Our client, a pharmaceutical company, was experiencing that reimbursement of their innovative, preventive treatment of severe migraine was restricted to a narrow subset of the eligible patient population. Our client suspected that treating a wider range of patients would be associated with an economic net gain for society. To determine if this was the case, they needed a study that demonstrated the value of their preventive medicines from a societal point of view.
We conducted a comprehensive real-world evidence (RWE) study to assess the societal impact of initiating preventive treatment with CGRP inhibitors in patients with chronic and episodic migraines. We collected real-world data in collaboration with two patient communities and two informal patient networks. Our analysis included evaluating socioeconomic benefits, such as increased labour supply, and health economic savings.
Our RWE study demonstrated that initiating CGRP inhibitor treatment in Danish patients with chronic and episodic migraine could lead to a total societal gain of 4.4 billion DKK per year, primarily driven by a socioeconomic component of 4,294 million DKK through increased labour supply. Health economic savings that are traditionally considered in health technology assessments, accounted for just 3% of the estimated societal gain.
We published our findings in a peer-reviewed manuscript and a white paper. Additionally, the study was presented at three major conferences: the MTIS in London, the Migraine Summit in Copenhagen, and the Health Political Summit in Copenhagen.
If you want to read more about our Healthcare & Life Sciences service, click the link below.
